Salwa Abugreen
Papers
1
Total Citations
12
H-Index
1
About
Dr. Salwa Abugreen is a leading ophthalmology researcher whose work centers on advancing treatments for neovascular age-related macular degeneration (nAMD), a primary cause of blindness worldwide. Her most significant contribution is the pivotal STAR trial, a randomized, double-masked, sham-controlled study investigating stereotactic radiotherapy as a novel approach to nAMD. This landmark 2024 publication (12 citations) demonstrated that ionizing radiation can mitigate key pathogenic processes underlying the disease, offering a potential alternative or adjunct to the standard anti-VEGF intravitreal injections. By exploring how radiotherapy reduces the treatment burden of frequent injections while maintaining visual outcomes, Dr. Abugreen’s research addresses a critical unmet need in retinal care. Her work bridges radiation oncology and ophthalmology, providing rigorous clinical evidence for a device-based therapy that could transform management paradigms for millions of patients. With this influential trial, she has established herself as a key figure in the search for durable, less invasive solutions for nAMD, positioning stereotactic radiotherapy as a promising frontier in retinal disease treatment.
Research Focus
Key Achievements
Top Papers
- 1